BSGM - バイオシグ・テクノロジ―ズ (BioSig Technologies Inc.) バイオシグ・テクノロジ―ズ

 BSGMのチャート


 BSGMの企業情報

symbol BSGM
会社名 BioSig Technologies Inc (バイオシグ・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 BioSig Technologies Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company's PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms and helps in making clinical decisions in real-time. It is also developing signal-processing tools which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System.   バイオシグ・テクノロジ―ズは米国の医療機器開発企業。生理学的信号から生物医学的信号の情報を抽出するための信号処理技術プラットフォ―ムの開発に従事。電気生理学研究やカテ―テル・アブレ―ション手術の現場で、すばやく正確な臨床判断を下す事を容易にするために開発された「PURE EP」システムが主力製品。本社所在地はカリフォルニア州ロサンゼルス。   BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. BioSig Technologies was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.
本社所在地 12424 Wilshire Blvd. Suite 745 Los Angeles CA 90025 USA
代表者氏名 Kenneth L. Londoner ケネス・L・ロンドン
代表者役職名 Executive Chairman of the Board Chief Executive Officer
電話番号 +1 310-820-8100
設立年月日 39845
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.biosigtech.com
nasdaq_url https://www.nasdaq.com/symbol/bsgm
adr_tso
EBITDA EBITDA(百万ドル) -15.38155
終値(lastsale) 5.27
時価総額(marketcap) 78723033.39
時価総額 時価総額(百万ドル) 77.82676
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 74.72862
当期純利益 当期純利益(百万ドル) -15.40750
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioSig Technologies Inc revenues was not reported. Net loss applicable to common stockholders increased 41% to $9M. Higher net loss reflects General and administrative increase of 88% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.67 to -$0.68.

 BSGMのテクニカル分析


 BSGMのニュース

   The Big COVID-19 Update at BioSig Technologies  2020/10/26 15:34:58 24/7 Wall street
   Westport's ViralClear opens phase 2 clinical trial for COVID-19 drug  2020/06/18 12:24:03 westfaironline
ViralClear, a subsidiary of BioSig Technologies in Westport, has opened a phase 2 clinical trial for its antiviral merimepodib to treat COVID-19 in adults.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'  2020/04/28 21:08:36 Benzinga
In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug candidates developed by Celgene spinoff Trek Therapeutics. Its test on COVID-19 patients yielded a 98.6% response rate. It was then that Dr. Jerome Zeldis, the founder of Trek and a board member at BioSig Technologies Inc (NASDAQ: BSGM ), urged BioSig CEO Ken Londoner to buy and advance the candidate, Londoner told Benzinga. “He called to say he believed he had a cure for COVID,” the BioSig CEO said. “We saw in vitro data from the Galveston biodefense lab and said, ‘wow, this drug is really far along.’” BioSig — a medtech company specializing in electrophysiology devices — took eight days to analyze the drug before completing the purchase in late March. By mid-April, it had filed to initiate a Phase 2 study. From Medtech To Biotech Vicromax is a broad-spectrum oral antiviral that demonstrated safety in humans and activity in Hepatitis B and C, herpes and other diseases in 12 prior clinical trials.
   The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update  2020/04/28 11:36:28 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) Masimo Corporation (NASDAQ: MASI ) Novo Nordisk A/S (NYSE: NVO ) OraSure Technologies, Inc. (NASDAQ: OSUR ) Quidel Corporation (NASDAQ: QDEL ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Repligen Corporation (NASDAQ: RGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Translate Bio Inc (NASDAQ: TBIO ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Vaxart Inc (NASDAQ: VXRT ) Vermillion, Inc. (NASDAQ: VRML ) West Pharmaceutical Services Inc. (NYSE: WST ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Zynex Inc. (NASDAQ: ZYXI ) None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.
   Westport's ViralClear opens phase 2 clinical trial for COVID-19 drug  2020/06/18 12:24:03 westfaironline
ViralClear, a subsidiary of BioSig Technologies in Westport, has opened a phase 2 clinical trial for its antiviral merimepodib to treat COVID-19 in adults.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'  2020/04/28 21:08:36 Benzinga
In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug candidates developed by Celgene spinoff Trek Therapeutics. Its test on COVID-19 patients yielded a 98.6% response rate. It was then that Dr. Jerome Zeldis, the founder of Trek and a board member at BioSig Technologies Inc (NASDAQ: BSGM ), urged BioSig CEO Ken Londoner to buy and advance the candidate, Londoner told Benzinga. “He called to say he believed he had a cure for COVID,” the BioSig CEO said. “We saw in vitro data from the Galveston biodefense lab and said, ‘wow, this drug is really far along.’” BioSig — a medtech company specializing in electrophysiology devices — took eight days to analyze the drug before completing the purchase in late March. By mid-April, it had filed to initiate a Phase 2 study. From Medtech To Biotech Vicromax is a broad-spectrum oral antiviral that demonstrated safety in humans and activity in Hepatitis B and C, herpes and other diseases in 12 prior clinical trials.
   The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update  2020/04/28 11:36:28 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) Masimo Corporation (NASDAQ: MASI ) Novo Nordisk A/S (NYSE: NVO ) OraSure Technologies, Inc. (NASDAQ: OSUR ) Quidel Corporation (NASDAQ: QDEL ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Repligen Corporation (NASDAQ: RGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Translate Bio Inc (NASDAQ: TBIO ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Vaxart Inc (NASDAQ: VXRT ) Vermillion, Inc. (NASDAQ: VRML ) West Pharmaceutical Services Inc. (NYSE: WST ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Zynex Inc. (NASDAQ: ZYXI ) None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.
   Why BioSig Technology's Stock Is Trading Higher Friday  2020/04/24 11:42:00 Benzinga
BioSig Technology (NASDAQ: BSGM) shares are trading higher on Friday after the company's subsidiary VirtalClear submitted an investigational new …
   Westport's ViralClear opens phase 2 clinical trial for COVID-19 drug  2020/06/18 12:24:03 westfaironline
ViralClear, a subsidiary of BioSig Technologies in Westport, has opened a phase 2 clinical trial for its antiviral merimepodib to treat COVID-19 in adults.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'  2020/04/28 21:08:36 Benzinga
In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug candidates developed by Celgene spinoff Trek Therapeutics. Its test on COVID-19 patients yielded a 98.6% response rate. It was then that Dr. Jerome Zeldis, the founder of Trek and a board member at BioSig Technologies Inc (NASDAQ: BSGM ), urged BioSig CEO Ken Londoner to buy and advance the candidate, Londoner told Benzinga. “He called to say he believed he had a cure for COVID,” the BioSig CEO said. “We saw in vitro data from the Galveston biodefense lab and said, ‘wow, this drug is really far along.’” BioSig — a medtech company specializing in electrophysiology devices — took eight days to analyze the drug before completing the purchase in late March. By mid-April, it had filed to initiate a Phase 2 study. From Medtech To Biotech Vicromax is a broad-spectrum oral antiviral that demonstrated safety in humans and activity in Hepatitis B and C, herpes and other diseases in 12 prior clinical trials.
   The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update  2020/04/28 11:36:28 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) AstraZeneca plc (NYSE: AZN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytosorbents Corp (NASDAQ: CTSO ) DexCom, Inc. (NASDAQ: DXCM ) Erytech Pharma SA (NASDAQ: ERYP ) Exelixis, Inc. (NASDAQ: EXEL ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Incyte Corporation (NASDAQ: INCY ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) Masimo Corporation (NASDAQ: MASI ) Novo Nordisk A/S (NYSE: NVO ) OraSure Technologies, Inc. (NASDAQ: OSUR ) Quidel Corporation (NASDAQ: QDEL ) REDHILL BIOPHAR/S ADR (NASDAQ: RDHL ) Repligen Corporation (NASDAQ: RGEN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Translate Bio Inc (NASDAQ: TBIO ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) Vaxart Inc (NASDAQ: VXRT ) Vermillion, Inc. (NASDAQ: VRML ) West Pharmaceutical Services Inc. (NYSE: WST ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Zynex Inc. (NASDAQ: ZYXI ) None of the Nasdaq- or NYSE-listed biotech/medical device/diagnostics company hit 52-week lows Monday.
   Why BioSig Technology's Stock Is Trading Higher Friday  2020/04/24 11:42:00 Benzinga
BioSig Technology (NASDAQ: BSGM) shares are trading higher on Friday after the company's subsidiary VirtalClear submitted an investigational new …

 関連キーワード  (先端医療機器_テクノロジ― 米国株 バイオシグ・テクノロジ―ズ BSGM BioSig Technologies Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)